Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system

Karen S. Slobod; Gregory H. Taylor; John T. Sandlund; Priscilla Furth; Kathleen J. Helton; John W. Sixbey

doi:10.1016/S0140-6736(00)02879-8

Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system

Karen S. Slobod, Gregory H. Taylor, John T. Sandlund, Priscilla Furth, Kathleen J. Helton, John W. Sixbey

Research output: Contribution to journal › Article › peer-review

69 Scopus citations

Abstract

Epstein-Barr virus (EBV) targeted therapeutic strategies for viral associated malignant diseases have received only perfunctory consideration, first, because latent herpesviruses have been intractable to antiviral chemotherapy and, second, because the role EBV has in maintenance of the malignant cell phenotype has been uncertain. Two patients with EBV related primary central nervous system lymphoma (PCNSL) in the setting of advanced AIDS, were treated with low dose hydroxyurea based on in vitro anti-EBV activity. The responses obtained here suggest the promise of antiviral approaches in select cancers.

Original language	English (US)
Pages (from-to)	1493-1494
Number of pages	2
Journal	Lancet
Volume	356
Issue number	9240
DOIs	https://doi.org/10.1016/S0140-6736(00)02879-8
State	Published - Oct 28 2000
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/S0140-6736(00)02879-8

Cite this

@article{b1dab987c1504c42a0393d0a2484f15e,

title = "Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system",

abstract = "Epstein-Barr virus (EBV) targeted therapeutic strategies for viral associated malignant diseases have received only perfunctory consideration, first, because latent herpesviruses have been intractable to antiviral chemotherapy and, second, because the role EBV has in maintenance of the malignant cell phenotype has been uncertain. Two patients with EBV related primary central nervous system lymphoma (PCNSL) in the setting of advanced AIDS, were treated with low dose hydroxyurea based on in vitro anti-EBV activity. The responses obtained here suggest the promise of antiviral approaches in select cancers.",

author = "Slobod, {Karen S.} and Taylor, {Gregory H.} and Sandlund, {John T.} and Priscilla Furth and Helton, {Kathleen J.} and Sixbey, {John W.}",

note = "Funding Information: We thank Andrew Freiberg and Stephen Thompson for excellent patient care; Yan-Jun Gan for molecular studies; Larry Kun for helpful discussions; James Langston for radiological review; and Nanna Howlett for patient care and chart review. This work was supported by Public Health Service grants CA-75541 (KSS) and CA67372 (JWS), by Cancer Center Support Grant CA21765, and by the American Lebanese Syrian Associated Charities (ALSAC).",

year = "2000",

month = oct,

day = "28",

doi = "10.1016/S0140-6736(00)02879-8",

language = "English (US)",

volume = "356",

pages = "1493--1494",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "9240",

}

TY - JOUR

T1 - Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system

AU - Slobod, Karen S.

AU - Taylor, Gregory H.

AU - Sandlund, John T.

AU - Furth, Priscilla

AU - Helton, Kathleen J.

AU - Sixbey, John W.

N1 - Funding Information: We thank Andrew Freiberg and Stephen Thompson for excellent patient care; Yan-Jun Gan for molecular studies; Larry Kun for helpful discussions; James Langston for radiological review; and Nanna Howlett for patient care and chart review. This work was supported by Public Health Service grants CA-75541 (KSS) and CA67372 (JWS), by Cancer Center Support Grant CA21765, and by the American Lebanese Syrian Associated Charities (ALSAC).

PY - 2000/10/28

Y1 - 2000/10/28

N2 - Epstein-Barr virus (EBV) targeted therapeutic strategies for viral associated malignant diseases have received only perfunctory consideration, first, because latent herpesviruses have been intractable to antiviral chemotherapy and, second, because the role EBV has in maintenance of the malignant cell phenotype has been uncertain. Two patients with EBV related primary central nervous system lymphoma (PCNSL) in the setting of advanced AIDS, were treated with low dose hydroxyurea based on in vitro anti-EBV activity. The responses obtained here suggest the promise of antiviral approaches in select cancers.

AB - Epstein-Barr virus (EBV) targeted therapeutic strategies for viral associated malignant diseases have received only perfunctory consideration, first, because latent herpesviruses have been intractable to antiviral chemotherapy and, second, because the role EBV has in maintenance of the malignant cell phenotype has been uncertain. Two patients with EBV related primary central nervous system lymphoma (PCNSL) in the setting of advanced AIDS, were treated with low dose hydroxyurea based on in vitro anti-EBV activity. The responses obtained here suggest the promise of antiviral approaches in select cancers.

UR - http://www.scopus.com/inward/record.url?scp=0034727395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034727395&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(00)02879-8

DO - 10.1016/S0140-6736(00)02879-8

M3 - Article

C2 - 11081539

AN - SCOPUS:0034727395

SN - 0140-6736

VL - 356

SP - 1493

EP - 1494

JO - Lancet

JF - Lancet

IS - 9240

ER -

Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this